The U.S. Food and Drug Administration (FDA) has accepted an investigational new drug application (IND) for ANK-700, a treatment candidate for multiple sclerosis (MS) that is being developed by the Swiss company Anokion.
With this approval, Anokion can enter clinical testing and is planning to initiate a multi-center, Phase 1 clinical trial to evaluate ANK-700 in people with MS by the end of the year.
“This IND marks the second clinical-stage program in our pipeline, and we look forward to initiating enrollment in the Phase 1 trial with ANK-700 later this year,” Simon Cooper, chief medical officer of Anokion, said in a press release.
The body’s immune system is responsible for defending it against bacteria, viruses, and other invaders. The processes by which the immune system recognizes possible threats is complicated, but at a simple level, the immune system is basically able to “see” everything as either “self” (a normal part of the body) or as “non-self” (not part of the body).
Anything recognized as “non-self” can trigger a protective immune response in the body, whereas anything identified as “self” should not. This ability of not attacking the body’s own cells and molecules, while still attacking anything recognized as foreign, is called immune tolerance.
Autoimmune diseases like MS are caused by a failure of immune tolerance; by definition, autoimmune diseases occur when the immune system attacks the body’s own molecules or cells.
ANK-700 was designed to “re-educate” the immune systems of people with MS, in order to restore tolerance.
The investigational therapy accomplishes this by modulating immune tolerance-associated processes in the liver. Specifically, ANK-700 is thought to affect a subset of immune cells called T-cells, which are believed to be involved in the development of MS.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?